Please assess the completion status of the following clinical trial:

Trial Title: Nadolol Versus Propranolol in Children With Infantile Hemangiomas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1-6 months corrected age~* Written parental informed consent~* At least one of the following:~  * Size: hemangioma \>1.5 cm on the face or \>3 cm on other body parts~ * Causing or with potential for functional impairment (e.g. amblyogenic IH, ulcerated hemangioma)~ * Causing or with potential for cosmetic disfigurement (e.g. nasal tip, glabella location)~Exclusion Criteria:~* Contraindications to beta-blockers~  * Hypotension~ * Bradycardia~ * Hypoglycemia~ * Cardiac disease associated with decreased ejection fraction and/or \> second degree heart block~ * Bronchospasm (including bronchial asthma)~ * Allergic rhinitis~* Corrected gestational age less than 1 month at screening~* Patients with PHACES cerebral arteriopathy at risk of stroke~* Patients and/or breastfeeding mothers receiving treatment with anti-arrhythmic agents, calcium channel blockers, ACE inhibitors, inotropic agents, vasodilators, hypoglycemic agents, neuroleptics, antiacids, benzodiazepines, thyroxine, warfarin~* Patients treated with an oral beta-blocker or other agent (e.g. systemic steroids, vincristine) within 2 weeks from randomization~* Patients treated with topical timolol within 1 week from randomization~* Vascular tumors other than infantile hemangioma (e.g. pyogenic granuloma, hemangioendothelioma)

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- Nadolol group (Type: ACTIVE_COMPARATOR): 40 study participants will take Nadolol (oral liquid suspension)
- Propranolol group (Type: ACTIVE_COMPARATOR): 40 study paticipants will take Propranolol (oral liquid suspension)

Based on this trial design, predict the completion outcome and termination type (if applicable).